Serum COMP and MMP-3 in Knee Osteoarthritis

Sponsor
Kanuni Sultan Suleyman Training and Research Hospital
Study ID
NCT07528872
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
40 Years - 75 Years
Healthy Volunteers
Accepted

Interventions

  • Observational Study — OTHER
    This is an observational study with no intervention. Participants will undergo clinical, radiological, and laboratory assessments, including serum biomarker analysis, without any therapeutic or experimental intervention.

Study Details

Knee osteoarthritis is a common degenerative joint disease characterized by pain, stiffness, and functional limitation, significantly affecting quality of life. In addition to mechanical factors, cartilage degradation and extracellular matrix remodeling play a key role in disease progression. Therefore, identifying reliable biomarkers reflecting disease severity has become an important research focus. Cartilage oligomeric matrix protein (COMP) is a structural component of cartilage associated with cartilage turnover, while matrix metalloproteinase-3 (MMP-3) is a proteolytic enzyme involved in extracellular matrix degradation. Both biomarkers have been suggested to be elevated in osteoarthritis and may reflect disease severity. The aim of this cross-sectional observational study is to evaluate the relationship between serum COMP and MMP-3 levels and clinical and radiological severity in patients with knee osteoarthritis. Pain severity will be assessed using the Visual Analog Scale (VAS), functional status with the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), and radiological severity with the Kellgren-Lawrence classification. Functional performance will also be evaluated using the 5 Times Sit-to-Stand Test. Additionally, serum COMP and MMP-3 levels will be compared between patients with knee osteoarthritis and healthy controls. The findings of this study are expected to contribute to a better understanding of the relationship between biochemical markers and clinical severity in osteoarthritis and may provide insight into their potential diagnostic and prognostic value.

Key Dates

First listed
Apr 14, 2026
Start date
Apr 30, 2026
Status verified
Apr 2026
Primary completion
May 15, 2026
Completion
Jun 1, 2026

Study Design

Enrollment
60 participants (estimated)

Arms

  • Arm: Knee Osteoarthritis
    Patients diagnosed with knee osteoarthritis
  • Arm: Healthy Control
    Age- and sex-matched healthy individuals without knee osteoarthritis

Primary Outcome Measure

Serum COMP and MMP-3 Levels [ Time Frame: At baseline ]

Central Contacts

Find similar trials

Nationwide
Osteoarthritis (other) trialsOrthopedics trialsMusculoskeletal disorders trials

Related Studies